220 related articles for article (PubMed ID: 16115935)
21. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.
Berntsen A; Geertsen PF; Svane IM
Eur Urol; 2006 Jul; 50(1):34-43. PubMed ID: 16675096
[TBL] [Abstract][Full Text] [Related]
23. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
[TBL] [Abstract][Full Text] [Related]
24. Historic evidence and future directions in clinical trial therapy of solid tumors.
Gollob JA; Bonomi P
Oncology (Williston Park); 2006 May; 20(6 Suppl 5):10-8. PubMed ID: 16773840
[TBL] [Abstract][Full Text] [Related]
25. Approaches to the development and marketing approval of drugs that prevent cancer.
Kelloff GJ; Johnson JR; Crowell JA; Boone CW; DeGeorge JJ; Steele VE; Mehta MU; Temeck JW; Schmidt WJ; Burke G
Cancer Epidemiol Biomarkers Prev; 1995; 4(1):1-10. PubMed ID: 7894318
[TBL] [Abstract][Full Text] [Related]
26. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
[TBL] [Abstract][Full Text] [Related]
28. Vaccine therapy in patients with renal cell carcinoma.
Van Poppel H; Joniau S; Van Gool SW
Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
[TBL] [Abstract][Full Text] [Related]
29. Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2.
Krastev Z; Koltchakov V; Tomov B; Koten JW
Hepatogastroenterology; 2003; 50(52):1006-16. PubMed ID: 12845968
[TBL] [Abstract][Full Text] [Related]
30. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
[TBL] [Abstract][Full Text] [Related]
31. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma.
Curti BD
Expert Rev Anticancer Ther; 2006 Jun; 6(6):905-9. PubMed ID: 16761934
[TBL] [Abstract][Full Text] [Related]
33. Thalidomide in solid tumors: the London experience.
Eisen TG
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):17-20. PubMed ID: 11204668
[TBL] [Abstract][Full Text] [Related]
34. Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
McBride D
ONS Connect; 2007 Jan; 22(1):14. PubMed ID: 17393636
[No Abstract] [Full Text] [Related]
35. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
Basche M; Gustafson DL; Holden SN; O'Bryant CL; Gore L; Witta S; Schultz MK; Morrow M; Levin A; Creese BR; Kangas M; Roberts K; Nguyen T; Davis K; Addison RS; Moore JC; Eckhardt SG
Clin Cancer Res; 2006 Sep; 12(18):5471-80. PubMed ID: 17000682
[TBL] [Abstract][Full Text] [Related]
36. Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?
Bradbury P; Seymour L
Cancer J; 2009; 15(5):354-60. PubMed ID: 19826353
[TBL] [Abstract][Full Text] [Related]
37. [A clinico-experimental study in metronomic therapy of disseminated solid tumors].
Chudenko VA; Moiseenko VM
Vopr Onkol; 2009; 55(3):327-34. PubMed ID: 19670733
[TBL] [Abstract][Full Text] [Related]
38. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
Ahmann FR; Meyskens FL; Moon TE; Durie BG; Salmon SE
Cancer Res; 1982 Nov; 42(11):4495-8. PubMed ID: 6897012
[TBL] [Abstract][Full Text] [Related]
39. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
[TBL] [Abstract][Full Text] [Related]
40. Vaccines for melanoma and renal cell carcinoma.
Kaufman HL
Semin Oncol; 2012 Jun; 39(3):263-75. PubMed ID: 22595049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]